BioLine RX LtdNASDAQ:BLRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.6965
- TODAY'S CHANGE (%)-0.0275 (-3.7983%)
- Bid / Lots0.6901/ 20
- Ask / Lots0.6999/ 1
- Open / Previous Close0.7125 / 0.7240
- Day Range
- 52 Week Range
- Volume308,590
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BLRX |
|---|---|---|
| 09:45 ET | 100 | 0.7339 |
| 09:48 ET | 6832 | 0.725 |
| 09:52 ET | 13970 | 0.74 |
| 09:57 ET | 27999 | 0.74 |
| 09:59 ET | 8200 | 0.748 |
| 10:01 ET | 11494 | 0.73 |
| 10:03 ET | 2700 | 0.7365 |
| 10:08 ET | 400 | 0.7365 |
| 10:19 ET | 192 | 0.744434 |
| 10:26 ET | 2000 | 0.745067 |
| 10:28 ET | 300 | 0.7365 |
| 10:32 ET | 1500 | 0.741475 |
| 10:35 ET | 185 | 0.73755 |
| 10:39 ET | 1999 | 0.73 |
| 10:48 ET | 100 | 0.7451 |
| 10:51 ET | 5600 | 0.7255 |
| 10:53 ET | 200 | 0.745 |
| 11:13 ET | 5589 | 0.725 |
| 11:15 ET | 300 | 0.7411 |
| 11:26 ET | 150 | 0.731 |
| 11:49 ET | 100 | 0.72637 |
| 11:56 ET | 177 | 0.7295 |
| 12:03 ET | 607 | 0.725 |
| 12:05 ET | 175 | 0.7325 |
| 12:14 ET | 1200 | 0.725 |
| 12:20 ET | 124 | 0.7251 |
| 12:25 ET | 1400 | 0.725 |
| 12:27 ET | 8050 | 0.7273 |
| 12:41 ET | 250 | 0.7101 |
| 12:54 ET | 155 | 0.729801 |
| 01:15 ET | 273 | 0.7299 |
| 01:37 ET | 1500 | 0.7137 |
| 02:09 ET | 1900 | 0.7102 |
| 02:11 ET | 10584 | 0.724 |
| 02:22 ET | 400 | 0.737 |
| 02:24 ET | 115 | 0.73165 |
| 02:27 ET | 131 | 0.73265 |
| 02:36 ET | 1937 | 0.7361 |
| 02:42 ET | 492 | 0.7262 |
| 02:47 ET | 4961 | 0.7263 |
| 02:49 ET | 700 | 0.7361 |
| 03:02 ET | 100 | 0.7361 |
| 03:03 ET | 17675 | 0.7294 |
| 03:12 ET | 84052 | 0.691 |
| 03:14 ET | 46205 | 0.698352 |
| 03:21 ET | 111 | 0.69425 |
| 03:23 ET | 3700 | 0.6911 |
| 03:25 ET | 2400 | 0.6921 |
| 03:27 ET | 900 | 0.6922 |
| 03:30 ET | 6840 | 0.6974 |
| 03:32 ET | 6635 | 0.6992 |
| 03:34 ET | 1800 | 0.6999 |
| 03:36 ET | 200 | 0.696 |
| 03:38 ET | 121 | 0.696 |
| 03:39 ET | 100 | 0.6921 |
| 03:41 ET | 2317 | 0.695 |
| 03:52 ET | 2000 | 0.6952 |
| 03:54 ET | 200 | 0.6965 |
| 03:57 ET | 1000 | 0.6978 |
| 03:59 ET | 420 | 0.6965 |
Jun 3, 2024
DJ BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co., from 12:45PM ET on Monday Jun 03, 2024 by Dow Jones
12:45PM ET on Monday Jun 03, 2024 by Dow Jones
May 30, 2024
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD), from 7:00AM ET on Thursday May 30, 2024 by Dow Jones
7:00AM ET on Thursday May 30, 2024 by Dow Jones
May 29, 2024
DJ BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co., from 10:34AM ET on Wednesday May 29, 2024 by Dow Jones
10:34AM ET on Wednesday May 29, 2024 by Dow Jones
May 28, 2024
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 7:00AM ET on Tuesday May 28, 2024 by Dow Jones
7:00AM ET on Tuesday May 28, 2024 by Dow JonesPress Release: BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 7:00AM ET on Tuesday May 28, 2024 by Dow Jones
7:00AM ET on Tuesday May 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioLine RX Ltd | 58.4M | -0.9x | --- |
LAVA Therapeutics NV | 59.4M | -2.1x | --- |
Dyadic International Inc | 63.7M | -8.2x | --- |
Kronos Bio Inc | 47.5M | -0.4x | --- |
Kezar Life Sciences Inc | 50.5M | -0.5x | --- |
Cue Biopharma Inc | 79.3M | -1.5x | --- |
Company Information
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Contact Information
- Headquarters
- Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Aharon Schwartz
- Chief Executive Officer
- Philip Serlin
- Chief Financial Officer
- Mali Zeevi
- Vice President - Development
- Ella Sorani
- Vice President-Clinical & Medical Affairs
- Abi Vainstein-Haras
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $58.4M |
|---|---|
Revenue (TTM) | $11.7M |
Shares Outstanding | 79.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.54 |
EPS | $-0.76 |
Book Value | $0.18 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | 5.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -391.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
